In a report released today, Matthew Biegler from Oppenheimer assigned a Buy rating to Homology Medicines (FIXX), with a price target of $24.00.
The post Oppenheimer Thinks Homology Medicines Stock is Going to Recover appeared first on Smarter Analyst.
In a report released today, Matthew Biegler from...

https://www.smarteranalyst.com/new-blurbs/oppenheimer-thinks-homology-medicines-stock-is-going-to-recover-2/

#SmarterAnalyst